The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis.

Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM. · 2020

Read The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. by Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7438974.txt.

Introduction

Stockdale and co-authors estimate how common hepatitis D virus infection is worldwide. The virus only infects people who carry hepatitis B. Its true spread and its share of liver disease were unclear.

The team pooled 282 studies from 95 countries, with tests on 120,293 hepatitis B carriers. They estimate 4.5% of carriers have hepatitis D antibodies. In liver clinics the share rose to 16.4%. In all, about 12 million people worldwide show past infection. Rates peak in Mongolia, Moldova, and parts of Africa, and in some risk groups. Hepatitis D may drive about 18% of cirrhosis and 20% of liver cancer among carriers. Better data are still needed.

Catalog record

CREATORStockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE44 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7438974

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis By Alexander J. Stockdale, Benno Kreuels, Marc Y.R. Henrion, Emanuele Giorgi, Irene Kyomuhangi, Catherine de Martel, Yvan Hutin, Anna Maria Geretti Published in: Journal of Hepatology DOI: 10.1016/j.jhep.2020.04.008 ABSTRACT Background and Aims There are uncertainties about the epidemic patterns of HDV infection and its contribution to the burden of liver disease. We estimated the global prevalence of HDV infection and explored its contribution to the development of cirrhosis and hepatocellular carcinoma (HCC) among HBsAg-positive people. Methods We searched Pubmed, EMBASE and Scopus for studies reporting on total or IgG anti-HDV among HBsAg-positive people. Anti-HDV prevalence was estimated using a binomial mixed model, weighting for study quality and population size. The population attributable fraction (PAF) of HDV to cirrhosis and HCC among HBsAg-positive people was estimated using random effects models. Results We included 282 studies, comprising 376 population samples from 95 countries, which together tested 120,293 HBsAg-positive people for anti-HDV. The estimated anti-HDV prevalence was 4.5% (95% CI 3.6–5.7) among all HBsAg-positive people and 16.4% (14.6–18.6) among those attending hepatology clinics. Worldwide, 0.16% (0.11–0.25) of the general population, totalling 12.0 (8.7–18.7) million people, were estimated to be anti-HDV positive. Prevalence among HBsAg-positive people was highest in Mongolia, the Republic of Moldova and countries in Western and Middle Africa, and was higher in injecting drug users, haemodialysis recipients, men who have sex with men, commercial sex workers, and those with HCV or HIV. Among HBsAg-positive people, preliminary PAF estimates of HDV were 18% (10–26) for cirrhosis and 20% (8–33) for HCC. Conclusions An estimated 12 million people worldwide have experienced HDV infection, with higher prevalence in certain geographic areas and populations. HDV is a significant contributor to HBV-associated liver disease. More quality data are needed to improve the precision of burden estimates. Lay summary We combined all available studies to estimate how many people with hepatitis B also have hepatitis D, a viral infection that only affects people with hepatitis B. About 1 in 22 people with hepatitis B also have hepatitis D, increasing to 1 in 6 when considering people with liver disease. Hepatitis D may cause about 1 in 6 of the cases of cirrhosis and 1 in 5 of the cases of liver cancer that occur in people with hepatitis B. Hepatitis D is an important contributor to the global burden of liver disease. See Editorial, pages 493–495 INTRODUCTION Globally, chronic infection with the HBV is an important cause of liver-related morbidity and mortality due to its widespread distribution. An estimated 257 to 291 million people are chronically infected with HBV and are at risk of cirrhosis and hepatocellular carcinoma (HCC).1,2 The proportion of cirrhosis attributable to HBV varies geographically according to HBV epidemiology, ranging from 6% in North America, to 6-21% in Latin America, 34–38% in sub-Saharan Africa, and 39% in East Asia.3 Worldwide, HBV is associated with a third of deaths from HCC.4 HDV is a satellite RNA virus that depends on HBV for propagation.5 It uses the HBsAg as a viral envelope and shares the same hepatocyte receptor for viral entry.6 HDV is among the smallest of viruses capable of causing human disease, yet HBV co-infection with HDV is the most severe form of viral hepatitis.5 HDV transmission follows 2 patterns. Infection occurring simultaneously with HBV can cause extensive hepatic necrosis and manifest as a severe or even fulminant hepatitis with a high case fatality rate.6 With recovery, simultaneous infection in adults usually results in clearance of both viruses.5 Super-infection of persons with chronic HBV infection typically results in HDV persistence, leading to accelerated progression to cirrhosis and an increased risk of HCC relative to chronic HBV infection alone.7 Due to variation in awareness and incomplete testing among HBsAg-positive people,8 issues with standardisation of confirmatory molecular diagnostic techniques,9 and a historical lack of effective treatment options,10 HDV ascertainment has been suboptimal, even in high-income settings. HDV may therefore have an under-recognised role in the causation of liver disease and liver-related deaths. Estimating HDV prevalence and the relative contribution of HDV towards liver disease, including among general populations and specific population groups, is critical to guide clinical care and policy formulation and inform effective public health interventions and development of new medicines. Yet, obtaining accurate estimates of HDV epidemiology is challenging for several reasons. Firstly, at the population level, large sample sizes are required to identify HBsAg-positive individuals prior to testing for HDV. In settings with low prevalence of HBV infection, sufficiently large surveys may not be feasible. Secondly, heterogeneity in HDV estimates might be expected because of variable and potentially evolving epidemic patterns, as well as variations in methodology. Thirdly, the selection criteria for HBsAg and subsequent HDV testing may lead to non-representative sampling. Therefore, careful assessment of potential biases and assessment of representativeness is required to synthesise epidemiological estimates of HDV prevalence. In a previous review, we identified foci of HDV endemicity in sub-Saharan Africa.11 This systematic review and meta-analysis aimed to identify and collate all globally available epidemiological data on HDV infection from January 1998 to January 2019. We aimed to describe the geographic distribution of HDV infection and to produce regional estimates of HDV infection among general populations, individuals attending hepatology clinics, and selected population groups, being mindful of potential sources of error. We further aimed to estimate the proportion of HBV-associated cirrhosis and HCC attributable to HDV. MATERIALS AND METHODS Outcomes of the analysis We performed a systematic review and meta-analysis of HDV prevalence in the 6 World Health Organisation (WHO) regions. The primary outcome was the prevalence of total or IgG anti-HDV among HBsAg-positive people. The prevalence of HDV RNA detection was estimated among individuals positive for HBsAg and anti-HDV based on assays employing PCR. The secondary outcome was the estimation of the population attributable fraction (PAF) of HDV among HBsAg-positive persons with cirrhosis and HCC. We conducted the study in accordance with the principles of the PRISMA and GATHER statements, and registered it with PROSPERO (CRD42018113039). Search method We searched PubMed, EMBASE and Scopus on 17th April 2018 for articles published since 1 January 1998 and repeated the search on 28 January 2019. The search strategy included synonyms of hepatitis D and terms describing HDV epidemiology and diagnosis (detailed in supplementary appendix 1). We included all languages. Articles in 8 languages unknown to the study team were translated into English. Between 18th and 21st February 2019, we also performed searches of the grey literature within the Global Health Data Exchange database, international health surveillance programmes, and official national health surveillance websites (listed in supplementary appendix 2), and reviewed surveys, censuses, vital statistics, and reports not already included in previously identified scientific publications. We contacted 21 corresponding authors to seek clarifications on their published data. We additionally searched GenBank (https://www.ncbi.nlm.nih.gov/genbank/) and the European Nucleotide Archive (http://www.ebi.ac.uk/ena) to retrieve HDV sequences and genotypes. Inclusion and exclusion criteria We included studies that described the geographic and clinical setting of participants with HBsAg and applied a systematic selection method to anti-HDV testing, whereby all eligible consenting participants, or a randomly selected representative sample were tested. Duplicate data, studies that commenced before 1988, and studies with evidence of selective or non-systematic testing were

Read the complete text